bluebird bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLUE research report →
Companywww.bluebirdbio.com
bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
- CEO
- Andrew Obenshain
- IPO
- 2013
- Employees
- 248
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $48.67M
- P/E
- -0.84
- P/S
- 0.63
- P/B
- -0.84
- EV/EBITDA
- -9.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 54.65%
- Op Margin
- -79.07%
- Net Margin
- -74.81%
- ROE
- 129.26%
- ROIC
- -46.84%
Growth & Income
- Revenue
- $83.81M · 184.12%
- Net Income
- $-240,715,000 · -13.59%
- EPS
- $-24.84 · -736.36%
- Op Income
- $-270,461,000
- FCF YoY
- -7.59%
Performance & Tape
- 52W High
- $28.60
- 52W Low
- $3.20
- 50D MA
- $4.42
- 200D MA
- $7.51
- Beta
- 0.36
- Avg Volume
- 576.32K
Get TickerSpark's AI analysis on BLUE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 30, 25 | Vittiglio Joseph | other | 1,143 |
| Jun 2, 25 | Vittiglio Joseph | other | 2,500 |
| Jun 2, 25 | Vittiglio Joseph | sell | 2,500 |
| May 30, 25 | Agwunobi John O | other | 1,323 |
| Jun 2, 25 | Agwunobi John O | sell | 1,245 |
| May 30, 25 | Vachon Mark | other | 1,252 |
| Jun 2, 25 | Vachon Mark | sell | 1,245 |
| May 30, 25 | Colvin Richard A | other | 3,552 |
| Jun 2, 25 | Colvin Richard A | other | 2,500 |
| Jun 2, 25 | Colvin Richard A | sell | 2,500 |
Our BLUE Coverage
We haven't published any research on BLUE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BLUE Report →